MedTrace Logo

Antioxidant Systems and Age-Related Macular Degeneration

NCT00668213 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2014-01-10

No results posted yet for this study

Summary

Objective:

The objective of this study was to determine whether the antioxidant supplements used in AREDS shifted the plasma pool of the AREDS subjects to a more reduced state. The AREDS subjects were randomly assigned to one of four treatment groups:

1. antioxidants (500mg Vitamin C, 4000IU Vitamin E, 15mg beta carotene)
2. zinc (80mg zinc oxide, 2mg cupric oxide)
3. antioxidants plus zinc;
4. placebo.

None of the subjects received supplemental GSH or cyst (e) ine.

Age-related macular degeneration (AMD) is the leading cause of severe visual impairment in elderly Americans, with an estimated 15 million people having some form of this disease. AMD primarily affects the central vision and many patients develop severe visual handicaps.

Currently there are no clear established understandings of the etiology or pathogenesis of this disease.

Conditions

  • Macular Degeneration

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Paul Sternberg, MD · Vanderbilt University Medical Center

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668213 on ClinicalTrials.gov